Literature DB >> 22406269

Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression.

Fanny Chalmin1, Grégoire Mignot, Mélanie Bruchard, Angélique Chevriaux, Frédérique Végran, Aziz Hichami, Sylvain Ladoire, Valentin Derangère, Julie Vincent, David Masson, Simon C Robson, Gerard Eberl, Jean René Pallandre, Christophe Borg, Bernhard Ryffel, Lionel Apetoh, Cédric Rébé, Francois Ghiringhelli.   

Abstract

Although Th17 cells are known to promote tissue inflammation and autoimmunity, their role during cancer progression remains elusive. Here, we showed that in vitro Th17 cells generated with the cytokines IL-6 and TGF-β expressed CD39 and CD73 ectonucleotidases, leading to adenosine release and the subsequent suppression of CD4(+) and CD8(+) T cell effector functions. The IL-6-mediated activation of the transcription factor Stat3 and the TGF-β-driven downregulation of Gfi-1 transcription factor were both essential for the expression of ectonucleotidases during Th17 cell differentiation. Stat3 supported whereas Gfi-1 repressed CD39 and CD73 expression by binding to their promoters. Accordingly, Th17 cells differentiated with IL-1β, IL-6, and IL-23 but without TGF-β did not express ectonucleotidases and were not immunosuppressive. Finally, adoptive transfer of Th17 cells induced by TGF-β and IL-6 promoted tumor growth in a CD39-dependent manner. Thus, ectonucleotidase expression supports the immunosuppressive fate of Th17 cells in cancer. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22406269     DOI: 10.1016/j.immuni.2011.12.019

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  150 in total

1.  A novel mechanism of B cell-mediated immune suppression through CD73 expression and adenosine production.

Authors:  Hiroaki Kaku; Kai Fan Cheng; Yousef Al-Abed; Thomas L Rothstein
Journal:  J Immunol       Date:  2014-11-12       Impact factor: 5.422

2.  CD73-mediated adenosine production promotes stem cell-like properties in mouse Tc17 cells.

Authors:  Felipe Flores-Santibáñez; Dominique Fernández; Daniel Meza; Gabriela Tejón; Leonardo Vargas; Lorena Varela-Nallar; Sebastián Arredondo; Victoria Guixé; Mario Rosemblatt; María Rosa Bono; Daniela Sauma
Journal:  Immunology       Date:  2015-09-29       Impact factor: 7.397

3.  CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression.

Authors:  Nathalie Bonnefoy; Jérémy Bastid; Gilles Alberici; Armand Bensussan; Jean-François Eliaou
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

4.  IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39.

Authors:  Ivan D Mascanfroni; Ada Yeste; Silvio M Vieira; Evan J Burns; Bonny Patel; Ido Sloma; Yan Wu; Lior Mayo; Rotem Ben-Hamo; Sol Efroni; Vijay K Kuchroo; Simon C Robson; Francisco J Quintana
Journal:  Nat Immunol       Date:  2013-09-01       Impact factor: 25.606

Review 5.  Transdisciplinary approach to restore pancreatic islet function.

Authors:  Carmen Fotino; R Damaris Molano; Camillo Ricordi; Antonello Pileggi
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

6.  Intestinal immunopathology is associated with decreased CD73-generated adenosine during lethal infection.

Authors:  V Francois; H Shehade; V Acolty; N Preyat; P Delrée; M Moser; G Oldenhove
Journal:  Mucosal Immunol       Date:  2014-11-12       Impact factor: 7.313

7.  IL-27 confers a protumorigenic activity of regulatory T cells via CD39.

Authors:  Young-Jun Park; Heeju Ryu; Garam Choi; Byung-Seok Kim; Eun Sook Hwang; Hun Sik Kim; Yeonseok Chung
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-04       Impact factor: 11.205

8.  An Elf2-like transcription factor acts as repressor of the mouse ecto-5'-nucleotidase gene expression in hepatic myofibroblasts.

Authors:  Michel Fausther; Elise G Lavoie; Jessica R Goree; Jonathan A Dranoff
Journal:  Purinergic Signal       Date:  2017-06-30       Impact factor: 3.765

Review 9.  Purinergic signaling during inflammation.

Authors:  Holger K Eltzschig; Michail V Sitkovsky; Simon C Robson
Journal:  N Engl J Med       Date:  2012-12-13       Impact factor: 91.245

Review 10.  Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers.

Authors:  M Segovia; S Russo; M R Girotti; G A Rabinovich; M Hill
Journal:  Clin Exp Immunol       Date:  2020-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.